The latest financial statement is for the year ending 2025-12-31.
| Cash Flow | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Gain on sale of kavo treatment unit and instrument business | - | 0 | 0 | 8,900 |
| Gain on equity investments, net | - | - | 3,600 | - |
| Net income (loss) | 47,000 | -1,118,600 | -100,200 | 243,100 |
| Depreciation | 40,100 | 40,800 | 36,000 | 31,800 |
| Amortization | 75,900 | 82,300 | 99,600 | 106,000 |
| Allowance for credit losses | 9,500 | 17,900 | 7,100 | 4,800 |
| Stock-based compensation expense | 37,600 | 35,300 | 30,700 | 30,500 |
| Gain on investments in rabbi trust, net | 3,800 | - | - | - |
| Impairment charges | - | - | - | 6,400 |
| Loss (gain) on equity investments, net | -6,200 | -400 | - | - |
| Loss (gain) on sale of property, plant and equipment | -1,800 | -2,800 | 5,400 | 1,900 |
| Restructuring charges | 0 | 0 | 1,300 | - |
| Goodwill and intangible asset impairments | 0 | 1,153,800 | 258,300 | - |
| Fixed assets impairments and other charges | 2,200 | 17,100 | 200 | - |
| Non-cash operating lease costs | 34,700 | 31,400 | 27,000 | 24,300 |
| Fair value adjustment of acquisition-related inventory | - | 0 | 0 | 9,500 |
| Inducement expense related to exchange of convertible notes | 0 | 0 | 28,500 | - |
| Amortization of debt discount and issuance costs | 4,200 | 4,900 | 4,600 | 4,100 |
| Deferred income taxes | -11,400 | 29,000 | 37,000 | 29,000 |
| Change in trade accounts receivable | 48,500 | -10,000 | 17,000 | 71,000 |
| Change in inventories | 29,100 | -3,600 | -35,100 | 39,900 |
| Restructuring charges | - | - | - | 4,700 |
| Change in trade accounts payable | 7,500 | -1,200 | -46,300 | 44,500 |
| Change in prepaid expenses and other assets | -7,700 | 6,700 | -3,300 | 11,700 |
| Change in accrued expenses and other liabilities | 116,000 | 134,500 | -12,000 | -133,000 |
| Proceeds from sale of kavo treatment unit and instrument business, net | - | 0 | 0 | 73,900 |
| Change in operating lease liabilities | 44,700 | 42,800 | 34,500 | 31,600 |
| Proceeds from the settlement of derivative financial instruments | - | 2,500 | 1,600 | 56,000 |
| Net cash provided by operating activities | 275,700 | 336,500 | 275,700 | 182,700 |
| Payments for additions to property, plant and equipment | 45,300 | 33,800 | 58,200 | 75,700 |
| Purchases of investments held in rabbi trust | 9,900 | 32,800 | - | - |
| Proceeds from sale of investments held in rabbi trust | 10,400 | 9,300 | - | - |
| Proceeds from sales of property, plant and equipment | 500 | 100 | 6,100 | 3,300 |
| Acquisitions, net of cash acquired | - | 0 | 0 | 696,200 |
| Proceeds from sale of equity investment | 0 | 400 | 10,700 | - |
| Repayment of borrowing | - | - | - | 500 |
| All other investing activities, net | 6,800 | 300 | 22,600 | 18,600 |
| Repayment of revolving line of credit | - | 0 | - | 124,000 |
| Net cash used in investing activities | -51,100 | -54,600 | -62,400 | -657,300 |
| Proceeds from stock option exercises | 2,800 | 2,400 | - | 21,800 |
| Payments Related To Tax Withholding For Share Based Compensation | - | - | - | 9,100 |
| Cash paid for treasury stock | 166,600 | - | - | - |
| Tax withholding payment related to net settlement of equity awards | 6,200 | 5,300 | - | 9,000 |
| Proceeds from issuance of convertible notes due 2028 | 0 | 0 | - | 0 |
| Debt issuance costs-A1750Convertible Senior Notes | 0 | 0 | - | - |
| Principal paid related to exchange of convertible notes due 2025 | 116,300 | 0 | - | - |
| Proceeds from borrowings | 0 | 0 | - | 300 |
| Repayment of borrowings | 0 | 100,000 | - | - |
| Proceeds from revolving line of credit | 115,400 | 0 | - | 124,000 |
| Payment of debt issuance and other deferred financing costs | - | - | - | 0 |
| Debt issuance costs-Other Borrowings | 0 | 0 | - | - |
| Purchase of capped calls related to issuance of convertible senior notes | - | - | - | 0 |
| All other financing activities | 0 | -800 | - | 0 |
| Net cash (used in) provided by financing activities | -170,900 | -103,700 | 118,900 | 12,500 |
| Effect of exchange rate changes on cash and cash equivalents | 88,900 | -49,100 | 900 | -4,600 |
| Net change in cash and cash equivalents | 142,600 | 129,100 | 333,100 | -466,700 |
| Cash and cash equivalents at beginning of period | 1,069,100 | - | - | - |
| Cash and cash equivalents at end of period | 1,211,700 | - | - | - |
Envista Holdings Corp (NVST)
Envista Holdings Corp (NVST)